Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/333

Title: Criteria for the validation of surrogate endpoints in randomized experiments
Authors: Buyse, Marc E.
Molenberghs, Geert
Keywords: Clinical trials
Multivariate data
Issue Date: 1998
Citation: Biometrics, 54(3). p. 1014-29
Abstract: The validation of surrogate endpoints has been studied by Prentice (1989, Statistics in Medicine 8, 431-440) and Freedman, Graubard, and Schatzkin (1992, Statistics in Medicine 11, 167-178). We extended their proposals in the cases where the surrogate and the final endpoints are both binary or normally distributed. Letting T and S be random variables that denote the true and surrogate endpoint, respectively, and Z be an indicator variable for treatment, Prentice's criteria are fulfilled if Z has a significant effect on T and on S, if S has a significant effect on T, and if Z has no effect on T given S. Freedman relaxed the latter criterion by estimating PE, the proportion of the effect of Z on T that is explained by S, and by requiring that the lower confidence limit of PE be larger than some proportion, say 0.5 or 0.75. This condition can only be verified if the treatment has a massively significant effect on the true endpoint, a rare situation. We argue that two other quantities must be considered in the validation of a surrogate endpoint: RE, the effect of Z on T relative to that of Z on S, and gamma Z, the association between S and T after adjustment for Z. A surrogate is said to be perfect at the individual level when there is a perfect association between the surrogate and the final endpoint after adjustment for treatment. A surrogate is said to be perfect at the population level if RE is 1. A perfect surrogate fulfills both conditions, in which case S and T are identical up to a deterministic transformation. Fieller's theorem is used for the estimation of PE, RE, and their respective confidence intervals. Logistic regression models and the global odds ratio model studied by Dale (1986, Biometrics, 42, 909-917) are used for binary endpoints. Linear models are employed for continuous endpoints. In order to be of practical value, the validation of surrogate endpoints is shown to require large numbers of observations.
URI: http://hdl.handle.net/1942/333
DOI: 10.2307/2533853
ISI #: 000080096700019
ISSN: 0006-341X
Type: Journal Contribution
Validation: ecoom, 2000
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version2.16 MBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.